This NDC is on FDA's drug shortage list (posted Apr 2, 2020)
Product Information
MIDAZOLAM HCL 2 MG/2 ML VIAL is a generic product labeled by Fresenius Kabi USA, LLC, priced at $0.2334 per ML under NDC 63323041112. Its NADAC has been published 242 times since May 20, 2015.
FDA first approved this application on Jun 20, 2000. Its Orange Book therapeutic-equivalence code is AP.
Strength
1 mg/mL
Manufacturer
Fresenius Kabi USA, LLCNDC
63323041112
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAMUSCULAR; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
MIDAZOLAM HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA075154FDA Approved
6/20/2000
TE Code
AP
On Market Since
7/14/2000
Pharmacological Classes
Price Statistics
The NADAC for MIDAZOLAM HCL 2 MG/2 ML VIAL has been published 242 times since May 20, 2015, and over the history we have for it it has declined 24.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2334 per ML |
|---|---|
| All-time high | $0.3151 (Feb 15, 2017) |
| All-time low | $0.1862 (Sep 18, 2024) |
| 52-week high | $0.2408 |
| 52-week low | $0.2269 |
| Median price | $0.2800 |
| Average price | $0.2627 |
| Largest weekly change | -33.5% (Sep 18, 2024) |
| Weeks tracked | 242 |
| Tracking since | May 20, 2015 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
MIDAZOLAM HYDROCHLORIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MIDAZOLAM HCL 2 MG/2 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for MIDAZOLAM HCL 2 MG/2 ML VIAL, manufactured by Fresenius Kabi USA, LLC, is $0.2334 per ML (NDC 63323041112), effective Sep 30, 2026.
How has the price of MIDAZOLAM HCL 2 MG/2 ML VIAL changed over time?
Over the history we have for it, the NADAC for MIDAZOLAM HCL 2 MG/2 ML VIAL has declined 24.4%. It has been tracked across 242 weekly CMS publications since May 20, 2015.
What are the highest and lowest recorded NADAC prices for MIDAZOLAM HCL 2 MG/2 ML VIAL?
Since May 20, 2015, the NADAC for MIDAZOLAM HCL 2 MG/2 ML VIAL has ranged from a low of $0.1862 (Sep 18, 2024) to a high of $0.3151 (Feb 15, 2017), with a median of $0.2800 per ML.
Are there cheaper alternatives to MIDAZOLAM HCL 2 MG/2 ML VIAL?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MIDAZOLAM HCL 1 MG/ML VIAL, is $0.2185 per ML — about 6% below MIDAZOLAM HCL 2 MG/2 ML VIAL.
Who manufactures MIDAZOLAM HCL 2 MG/2 ML VIAL?
MIDAZOLAM HCL 2 MG/2 ML VIAL (NDC 63323041112) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.
Is MIDAZOLAM HCL 2 MG/2 ML VIAL in shortage?
Yes — NDC 63323041112 is currently listed in FDA's drug shortage database (posted Apr 2, 2020).